Normalisation of Haemostasis in Haemophilia A

Kristina Standeven
{"title":"Normalisation of Haemostasis in Haemophilia A","authors":"Kristina Standeven","doi":"10.33590/emjhematol/tupo1598","DOIUrl":null,"url":null,"abstract":"Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, joint damage, psychosocial impacts, restrictions in daily activities, and limitations in physical activities. Cédric Hermans, Professor at the Cliniques Universitaires Saint-Luc, Brussels, Belgium, outlined how ambitious treatment goals, beyond converting severe haemophilia A into a more moderate or mild form of the condition, are required. With new treatments, it will be possible to target FVIII activity levels in the non-haemophilia range (>40 IU/dL), allowing PwHA to reach freedom from bleeds, leading to a haemophilia-free mindset, and comparable quality of life (QoL) with their peers. Maria Elisa Mancuso, Senior Haematology Consultant at IRCCS Humanitas Research Hospital, Milan, Italy, highlighted the evolution of haemophilia A treatments; she showed clinical evidence that a zero-bleed goal may require sustained FVIII activity levels >40 IU/dL for complete protection against all types of bleeds and joint damage. Rubén Berrueco, Paediatric Haematologist at the Sant Joan de Déu Barcelona Children’s Hospital, Spain, described the haemophilia paediatric patient journey, and how uncertainties related to bleeds and treatment burden pose unique challenges for children and their caregivers. He presented his perspectives on challenges with current treatments (e.g., delayed inhibitor development, subclinical bleeds, and lack of skills for intravenous administration) and the need to improve self-autonomy and decrease hospital dependency. New treatments to achieve the non-haemophilia range of FVIII could address current unmet needs. The experts discussed that treatments for many diseases (e.g., diabetes, hypertension) aim to restore normal values (blood sugar, blood pressure), which was not the case until now for haemophilia. A more patient-centred approach with treatments targeting normal values of FVIII could allow all PwHA to become mentally and physically liberated from the constraints of their condition, and to live with optimised health and well-being.","PeriodicalId":509115,"journal":{"name":"EMJ Hematology","volume":"102 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjhematol/tupo1598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, joint damage, psychosocial impacts, restrictions in daily activities, and limitations in physical activities. Cédric Hermans, Professor at the Cliniques Universitaires Saint-Luc, Brussels, Belgium, outlined how ambitious treatment goals, beyond converting severe haemophilia A into a more moderate or mild form of the condition, are required. With new treatments, it will be possible to target FVIII activity levels in the non-haemophilia range (>40 IU/dL), allowing PwHA to reach freedom from bleeds, leading to a haemophilia-free mindset, and comparable quality of life (QoL) with their peers. Maria Elisa Mancuso, Senior Haematology Consultant at IRCCS Humanitas Research Hospital, Milan, Italy, highlighted the evolution of haemophilia A treatments; she showed clinical evidence that a zero-bleed goal may require sustained FVIII activity levels >40 IU/dL for complete protection against all types of bleeds and joint damage. Rubén Berrueco, Paediatric Haematologist at the Sant Joan de Déu Barcelona Children’s Hospital, Spain, described the haemophilia paediatric patient journey, and how uncertainties related to bleeds and treatment burden pose unique challenges for children and their caregivers. He presented his perspectives on challenges with current treatments (e.g., delayed inhibitor development, subclinical bleeds, and lack of skills for intravenous administration) and the need to improve self-autonomy and decrease hospital dependency. New treatments to achieve the non-haemophilia range of FVIII could address current unmet needs. The experts discussed that treatments for many diseases (e.g., diabetes, hypertension) aim to restore normal values (blood sugar, blood pressure), which was not the case until now for haemophilia. A more patient-centred approach with treatments targeting normal values of FVIII could allow all PwHA to become mentally and physically liberated from the constraints of their condition, and to live with optimised health and well-being.
血友病 A 的止血正常化
A 型血友病(因子 VIII [FVIII]水平≤40 IU/dL)是一种慢性疾病,其后果不仅仅是出血并发症。许多 A 型血友病患者(PwHA)会感到疼痛、关节损伤、社会心理影响、日常活动受限以及身体活动受限。比利时布鲁塞尔圣卢克大学诊所(Cliniques Universitaires Saint-Luc)教授塞德里克-赫尔曼斯(Cédric Hermans)概述了如何实现雄心勃勃的治疗目标,而不仅仅是将重度甲型血友病转变为中度或轻度血友病。有了新的治疗方法,就有可能将 FVIII 活性水平控制在非血友病范围内(>40 IU/dL),让 PwHA 达到不出血的程度,从而实现无血友病的心态以及与同龄人相当的生活质量(QoL)。意大利米兰 IRCCS Humanitas 研究医院高级血液学顾问 Maria Elisa Mancuso 重点介绍了甲型血友病治疗方法的演变;她展示的临床证据表明,要实现零出血目标,可能需要 FVIII 活性水平持续大于 40 IU/dL,才能完全避免各种类型的出血和关节损伤。西班牙 Sant Joan de Déu 巴塞罗那儿童医院儿科血液病专家 Rubén Berrueco 讲述了血友病儿科患者的治疗历程,以及出血和治疗负担的不确定性如何给儿童及其护理人员带来独特的挑战。他从自己的角度阐述了当前治疗面临的挑战(如抑制剂发育迟缓、亚临床出血、缺乏静脉给药技能等),以及提高自主性和减少对医院依赖的必要性。实现 FVIII 非血友病范围的新疗法可以满足当前尚未满足的需求。专家们讨论说,许多疾病(如糖尿病、高血压)的治疗都以恢复正常值(血糖、血压)为目标,而血友病的治疗迄今为止还不是这样。以患者为中心,针对 FVIII 正常值进行治疗的方法可以让所有血友病患者从精神和身体上摆脱病情的束缚,以最佳的健康和幸福状态生活。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信